Skip to main content
SpringerLink
Log in

Seminomtherapie im klinischen Stadium I

Stellenwert der adjuvanten Therapie beim Seminom

  • Fortbildung
  • Published:
Uro-News Aims and scope

Die S3-Leitlinie empfielt als adjuvante Therapie beim Seminom generell Surveillance — unabhängig vom Risikoprofil. Muss man davon abweichen, führt sie allerdings verschiedene Alternativen auf. Warum hier Unklarheit besteht, soll der folgende Artikel aufzeigen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Jones WG et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organization for the Research and Treatment of Cancer Trial 30942 (ISRCTN 18525328) J Clin Oncol. 2005; 23: 1200–8

    Article  Google Scholar 

  2. Oliver RT et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet. 2005; 366: 293–300

    Article  CAS  Google Scholar 

  3. Oliver RT et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma; mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol. 2011; 29: 957–62

    Article  CAS  Google Scholar 

  4. Warde P et al. Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. J Urol. 1997; 15: 1000–7

    Google Scholar 

  5. Krege S et al. European Consensus Conference on Diagnosis and treatment of germ cell cancer. A report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part I. Eur Urol. 2008; 53: 478–96

    Article  Google Scholar 

  6. Aparicio J et al. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group Study. J Clin Oncol. 2011; 29: 4677–81

    Article  Google Scholar 

  7. Aparicio J et al. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). Ann Oncol. 2014; 25: 2173–78

    Article  CAS  Google Scholar 

  8. Tandstad T et al. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group. Ann Oncol. 2016; 27: 1299–304

    Article  CAS  Google Scholar 

  9. Dieckmann KP et al. Testicular seminoma clinical stage 1: treatment outcome on a routine care level. J Cancer Res Clin Oncol. 2016; 142: 1599–607

    Article  CAS  Google Scholar 

  10. Boormans JL et al. Testicular tumour size and rete testis invasion as prognostic factors for the risk of relapse of clinical stage I seminoma testis patients under surveillance: a systematic review by the Testicular Cancer Guidelines Panel. Eur Urol. 2017; https://doi.org/10.1016/j.eururo.2017.09.025

    Article  Google Scholar 

  11. Zengerling F et al. Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance — a systematic review. Urol Oncol. 2018; 36: 448–58

    Article  Google Scholar 

  12. Chung P et al. Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance. Cancer Med. 2015; 4: 155–60

    Article  Google Scholar 

  13. Fischer S et al. Outcome of men with relapse after adjuvant carboplatin for clinical stage I seminoma. J Clin Oncol. 2017; 35: 194–200

    Article  Google Scholar 

  14. Mortensen MS et al. A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol. 2014; 66: 1172–8

    Article  Google Scholar 

  15. Chau C et al. treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumor: results from a 17-year UK experience. Ann Oncol. 2015; 26: 1865–70

    Article  CAS  Google Scholar 

  16. Powles T et al. The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol. 2008; 19: 443–7

    Article  CAS  Google Scholar 

  17. Ruf CG et al. Adjuvant carboplatin therapy in patients with clinical stage 1 testicular seminoma: is long-term morbidity increased? J Cancer Res Clin Oncol. 2019; 145: 2335–42

    Article  CAS  Google Scholar 

  18. Horwich A et al. Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br J Cancer. 2014; 110: 256–63

    Article  CAS  Google Scholar 

  19. Patel HD et al. Radiotherapy for stage I and II testicular seminomas: Secondary malignancies and survival. Urol Oncol. 2017; https://doi.org/10.1016/j.urolonc.2017.06.051

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Urologie, Kinderurologie und urologische Onkologie, Ev. Kliniken Essen Mitte, Henricistr. 92, 45136, Essen, Deutschland

    Susanne Krege

Authors
  1. Susanne Krege
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susanne Krege.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Krege, S. Stellenwert der adjuvanten Therapie beim Seminom. Uro-News 23, 35–37 (2019). https://doi.org/10.1007/s00092-019-3008-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00092-019-3008-1

Search

Navigation